TP53 and neoplasm: The most advanced of these is the small molecule PRIMA-1MET (APR-246) that has successfully completed Phase I/II clinical trials, where it was observed that it could induce p53-dependent biological effects in tumour cells in vivo (Lehmann et al., 2012).